Table 2.
All women (N = 848) | Women living with HIV (N = 468) |
Women without HIV (N = 380) |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mis carriage (n=250, 29%) |
Live birth (n=598, 71%) |
p-value | Mis carriage (n=140, 30%) |
Live birth (n=328, 70%) |
p-value | Mis carriage (n=110, 29%) |
Live birth (n=270, 71%) |
p-value | ||||||||
n | % | n | % | n | % | n | % | n | % | n | % | |||||
Variables (previous visit) | ||||||||||||||||
Age group | <25 | 63 | 25 | 97 | 16 | 0.011 | 29 | 21 | 38 | 12 | 0.062 | 34 | 31 | 59 | 22 | 0.138 |
25-30 | 50 | 20 | 155 | 26 | 29 | 21 | 90 | 27 | 21 | 19 | 65 | 24 | ||||
30-35 | 65 | 26 | 189 | 32 | 41 | 29 | 105 | 32 | 24 | 22 | 84 | 31 | ||||
>35 | 72 | 29 | 157 | 26 | 41 | 29 | 95 | 29 | 31 | 28 | 62 | 23 | ||||
Alcohol use | Abstain | 118 | 49 | 450 | 81 | <.0001 | 76 | 56 | 263 | 84 | <.0001 | 42 | 40 | 187 | 77 | <.0001 |
Drinkers | 123 | 51 | 108 | 19 | 60 | 44 | 51 | 16 | 63 | 60 | 57 | 23 | ||||
Alcohol use frequency | Abstain | 118 | 49 | 450 | 81 | <.0001 | 76 | 56 | 263 | 84 | <.0001 | 42 | 40 | 187 | 77 | <.0001 |
0-7 | 101 | 42 | 89 | 16 | 46 | 34 | 45 | 14 | 55 | 52 | 44 | 18 | ||||
>7 | 22 | 9 | 19 | 3 | 14 | 10 | 6 | 2 | 8 | 8 | 13 | 5 | ||||
Marijuana use | No | 171 | 70 | 492 | 88 | <.0001 | 105 | 77 | 288 | 91 | <.0001 | 66 | 62 | 204 | 83 | <.0001 |
Yes | 72 | 30 | 68 | 12 | 32 | 23 | 27 | 9 | 40 | 38 | 41 | 17 | ||||
Marijuana use frequency | None | 171 | 71 | 492 | 88 | <.0001 | 105 | 77 | 288 | 91 | 0.001 | 66 | 64 | 204 | 84 | 0.001 |
Less than weekly | 15 | 6 | 24 | 4 | 6 | 4 | 11 | 3 | 9 | 9 | 13 | 5 | ||||
1-6 times/week | 22 | 9 | 16 | 3 | 12 | 9 | 7 | 2 | 10 | 10 | 9 | 4 | ||||
At least daily | 32 | 13 | 27 | 5 | 14 | 10 | 9 | 3 | 18 | 17 | 18 | 7 | ||||
Cigarette smoking | No | 120 | 49 | 401 | 72 | <.0001 | 65 | 47 | 231 | 73 | <.0001 | 55 | 52 | 170 | 69 | 0.003 |
Yes | 123 | 51 | 159 | 28 | 72 | 53 | 84 | 27 | 51 | 48 | 75 | 31 | ||||
Health related* | No | 193 | 77 | 477 | 80 | 0.414 | 108 | 77 | 256 | 78 | 0.829 | 85 | 77 | 221 | 82 | 0.334 |
Yes | 57 | 23 | 121 | 20 | 32 | 23 | 72 | 22 | 25 | 23 | 49 | 18 | ||||
Pregnancy year | 1994-1997 | 50 | 20 | 86 | 14 | 0.066 | 36 | 26 | 49 | 15 | 0.023 | 14 | 13 | 37 | 14 | 0.655 |
1998-2001 | 46 | 18 | 85 | 14 | 29 | 21 | 57 | 18 | 17 | 16 | 28 | 10 | ||||
2002-5 | 74 | 30 | 215 | 36 | 39 | 28 | 124 | 38 | 35 | 32 | 91 | 34 | ||||
≥2006 | 79 | 32 | 208 | 35 | 36 | 26 | 95 | 29 | 43 | 39 | 113 | 42 | ||||
Any STI diagnosis** | No | 211 | 86 | 493 | 88 | 0.564 | 114 | 83 | 265 | 84 | 0.688 | 97 | 92 | 228 | 93 | 0.608 |
Yes | 33 | 14 | 67 | 12 | 24 | 17 | 50 | 16 | 9 | 8 | 17 | 7 | ||||
Yeast infection | No | 200 | 82 | 434 | 78 | 0.120 | 111 | 81 | 237 | 75 | 0.177 | 89 | 84 | 197 | 80 | 0.509 |
Yes | 43 | 18 | 126 | 23 | 26 | 19 | 78 | 25 | 17 | 16 | 48 | 20 | ||||
BV infection | No | 186 | 80 | 356 | 85 | 0.134 | 97 | 73 | 192 | 81 | 0.066 | 89 | 90 | 164 | 90 | 0.873 |
Yes | 46 | 20 | 63 | 15 | 36 | 27 | 44 | 19 | 10 | 10 | 19 | 10 | ||||
LEEP procedure | No | 248 | 99 | 596 | 100 | 0.389 | 138 | 99 | 327 | 100 | 0.208 | 110 | 100 | 269 | 100 | n/a |
Yes | 2 | 1 | 2 | 0 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | ||||
HIV viral load | ≥4 log10 copies/mL | 45 | 33 | 43 | 14 | <.0001 | ||||||||||
<4 log10 copies/mL | 90 | 67 | 266 | 86 | ||||||||||||
CD4 count <500 cells/μL | No | 57 | 43 | 127 | 41 | 0.759 | ||||||||||
Yes | 77 | 57 | 183 | 59 | ||||||||||||
cART regimen | II, NRTI, NNRTI | 23 | 17 | 71 | 22 | <.0001 | ||||||||||
PI | 28 | 20 | 128 | 40 | ||||||||||||
No cART | 87 | 63 | 121 | 38 | ||||||||||||
AIDS defining illness | No | 98 | 70 | 247 | 75 | 0.235 | ||||||||||
Yes | 42 | 30 | 81 | 25 |
WIHS: Women's Interagency HIV Study; cART: combination highly active antiretroviral therapy; II: integrase inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitors; NRTI: nucleoside reverse transcriptase inhibitors; PI: protease inhibitor; STI: sexually transmitted infection; BV: bacterial vaginosis; LEEP: loop electrosurgical excision procedure
Includes stroke, cancer, myocardial infarction, high blood pressure pulmonary embolism, diabetes
Includes gonorrhea, trichomonas, herpes-2, genital warts, syphilis, chlamydia
‘n’ is given over all study intervals
p-values are two-tailed